Immatics
GermanyWho owns Immatics?
Immatics is a German Biotech company, currently owned by Athos since 2020 and dievini Hopp BioTech holding. It changed hands in 2020, when Wellington Partners and MIG Capital sold.
Hand-verified · updated 2026-09-30
Open JSON · CC-BY
Key facts
- ·Co-held by dievini Hopp BioTech holding and Athos since 2006.
- ·Average hold across 3 realized cycles: 12 years.
- ·4 distinct PE sponsors across ownership cycles.
Ownership history
5 ownership periods · co-invest detected
Wellington Partners took Immatics public via IPO in 2020 after 16 years.
MIG Capital took Immatics public via IPO in 2020 after 10 years.
MIG Capital took Immatics public via IPO in 2020 after 10 years.
More from dievini Hopp BioTech holding (Evergreen Balance Sheet)
Other portfolio companies in the same fund.
More PE-backed in Biotech
Comparable biotech deals from other GPs.
USQuestions
Who owns Immatics?
Immatics is currently owned by Athos and dievini Hopp BioTech holding, through dievini Hopp BioTech holding (Evergreen Balance Sheet), since 2020.
When did Athos and 1 other acquire Immatics?
Athos and 1 other acquired Immatics in 2020.
Who did Immatics sell to?
Wellington Partners and MIG Capital sold Immatics to Athos in 2020 (IPO). MIG Capital sold Immatics to ARYA Sciences Acquisition in 2020 (IPO).
Who has owned Immatics over time?
Immatics has been through 5 private-equity ownership periods: Wellington Partners · via Wellington Partners Life Sciences · 2004–2020 · sold to Athos · (IPO); dievini Hopp BioTech holding · via dievini Hopp BioTech holding (Evergreen Balance Sheet) · since 2006; MIG Capital · via MIG Fonds 5 · 2010–2020 · sold to Athos · (IPO); MIG Capital · via MIG Fonds 8 · 2010–2020 · sold to ARYA Sciences Acquisition · (IPO); Athos · via Athos Evergreen Life Sciences · since 2020.